Table 1 JAK inhibitors in clinical trials

INCB018424 (Ruxolitinib)

JAK1 & 2

NR

III: Reported

PMF, Post ET/PV MF,

III: recruiting

PV (intolerant or resistant to HU)

FDA Approved

II: Recruiting

PV, ET

[62–67]

I/II: Recruiting

AML/ALL (Relapse/Refractory)

II: Completed

MM (Relapse/Refractory)

II: Recruiting

DLBCL/T-Cell Lymphoma

II: Active

Advanced Hem Malignancies

SAR302503

JAK2

FLT3

III: Recruiting

PMF

(TG101348)

RET

II: Recruiting

PV, ET

[70]

CEP-701

JAK2

FLT3

II: Completed

ET, PV

(Lestaurtinib)

JAK3

VEGFR2

II: Completed

AML (FLT3)

[71, 72]

TRKA

III: Recruiting

ALL (children)

RET

II: Recruiting

PMF

CYT387

JAK1,2

PKD3, PRKD1, CDK2, ROCK2, JNK1

II: Recruiting

PMF, Post PV/ET MF

[77, 78]

Tyk2

SB1518

JAK2

FLT3

II: Completed

PMF

[83, 84]

II: Completed

Adv Myeloid malignancies

II: Completed

Adv Lymphoid malignancies

II: Recruiting

MDS

LY2784544

JAK2V617F

NA

I/II: Recruiting

PMF, ET, PV

[85]

XL019

JAK2

NA

I: Terminated

PMF

[86]

AZD1480

JAK1-3

FGFR1, FLT4, ARK5, ALK4, Aurora-A

I/II: Active

PMF, Post ET/PV MF

[91]

BMS-911543

JAK2

No information

I/II: active

PMF

[90]

NS018

JAK2

Src Kinases

I/II: active

PMF, Post ET/PV MF

[89]